JP2016514148A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514148A5 JP2016514148A5 JP2016501850A JP2016501850A JP2016514148A5 JP 2016514148 A5 JP2016514148 A5 JP 2016514148A5 JP 2016501850 A JP2016501850 A JP 2016501850A JP 2016501850 A JP2016501850 A JP 2016501850A JP 2016514148 A5 JP2016514148 A5 JP 2016514148A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antibody
- nos
- acid sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361778540P | 2013-03-13 | 2013-03-13 | |
| US61/778,540 | 2013-03-13 | ||
| US201361808381P | 2013-04-04 | 2013-04-04 | |
| US61/808,381 | 2013-04-04 | ||
| PCT/US2014/025441 WO2014159911A1 (en) | 2013-03-13 | 2014-03-13 | Compositions comprising anti-cd38 antibodies and carfilzomib |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016514148A JP2016514148A (ja) | 2016-05-19 |
| JP2016514148A5 true JP2016514148A5 (enExample) | 2017-06-15 |
| JP6279065B2 JP6279065B2 (ja) | 2018-02-14 |
Family
ID=51625288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501850A Active JP6279065B2 (ja) | 2013-03-13 | 2014-03-13 | 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US20160022813A1 (enExample) |
| EP (2) | EP3769783A1 (enExample) |
| JP (1) | JP6279065B2 (enExample) |
| KR (2) | KR102241868B1 (enExample) |
| CN (3) | CN112043826A (enExample) |
| AU (1) | AU2014244333B2 (enExample) |
| CA (1) | CA2904630A1 (enExample) |
| ES (1) | ES2808565T3 (enExample) |
| IL (2) | IL241407B (enExample) |
| MX (1) | MX373308B (enExample) |
| MY (1) | MY175418A (enExample) |
| PL (1) | PL2968555T3 (enExample) |
| PT (1) | PT2968555T (enExample) |
| RU (2) | RU2670127C2 (enExample) |
| SG (3) | SG10201913777XA (enExample) |
| WO (1) | WO2014159911A1 (enExample) |
| ZA (1) | ZA201507310B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| HRP20171964T1 (hr) | 2012-09-25 | 2018-02-23 | Morphosys Ag | Kombinacije i njihova upotreba |
| US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| SG10201913777XA (en) | 2013-03-13 | 2020-03-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
| MX373301B (es) * | 2013-10-31 | 2020-04-24 | Sanofi Sa | Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos. |
| US10617757B2 (en) | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| MA41555A (fr) * | 2015-02-17 | 2017-12-26 | Millennium Pharm Inc | Polythérapie pour le traitement du cancer |
| EP3421494A1 (en) * | 2017-06-29 | 2019-01-02 | Sanofi | Use of isatuximab in combination with an anti-pd-1 antibody |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| BR112021000065A2 (pt) * | 2018-07-10 | 2021-04-06 | Sanofi | Terapias de combinação contra câncer direcionando cd38 e tgf-beta |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| AU2020397170A1 (en) | 2019-12-05 | 2022-07-21 | Sanofi-Aventis U.S. Llc | Formulations of anti-CD38 antibodies for subcutaneous administration |
| TWI887310B (zh) * | 2019-12-06 | 2025-06-21 | 美商賽諾菲 安萬特美國有限責任公司 | 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途 |
| CN118217957A (zh) * | 2024-03-18 | 2024-06-21 | 重庆迈德凯医药有限公司 | 一种卡非佐米杂质分子印迹材料及其制备方法和卡非佐米的精制方法 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US20070042436A1 (en) * | 2000-10-17 | 2007-02-22 | Lund Frances E | CD38 modulated chemotaxis |
| RU2402568C2 (ru) * | 2004-02-06 | 2010-10-27 | МорфоСис АГ | Человеческие анти-cd38-антитела и их применение |
| ATE494298T1 (de) | 2004-04-15 | 2011-01-15 | Proteolix Inc | Verbindungen zur proteasomenzymhemmung |
| US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
| EP2261236B1 (en) | 2004-12-07 | 2015-07-15 | Onyx Therapeutics, Inc. | Composition for proteasome inhibition |
| US8207303B2 (en) | 2005-02-18 | 2012-06-26 | Medarex, Inc. | Monoclonal antibodies against CD30 lacking in fucosyl residues |
| CN101287764B (zh) * | 2005-10-12 | 2013-11-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| CN101534860B (zh) * | 2006-08-07 | 2013-03-27 | 艾伯特生物治疗学公司 | 使用抗cs1-抗体治疗多发性骨髓瘤的组合物和方法 |
| US20090270419A1 (en) | 2006-09-15 | 2009-10-29 | Janine Arts | Combinations of class-i specific histone deacetylase inhibitors with proteasome inhibitors |
| PL2081595T3 (pl) * | 2006-09-26 | 2019-11-29 | Genmab As | Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2195023B1 (en) | 2007-08-29 | 2018-03-07 | Sanofi | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
| KR20110028450A (ko) * | 2008-06-16 | 2011-03-18 | 이뮤노젠 아이엔씨 | 새로운 상승 효과 |
| JP5675629B2 (ja) * | 2008-10-21 | 2015-02-25 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ペプチドエポキシケトンを用いた併用療法 |
| KR20170060179A (ko) * | 2008-11-13 | 2017-05-31 | 길리아드 칼리스토가 엘엘씨 | 혈액 종양에 대한 요법 |
| EP2191842A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| CA2761120A1 (en) * | 2009-05-06 | 2010-11-11 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
| US8877899B2 (en) * | 2010-09-27 | 2014-11-04 | Morphosys Ag | Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL |
| UA112062C2 (uk) * | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| EP3974453A3 (en) * | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| WO2012135528A2 (en) * | 2011-03-29 | 2012-10-04 | Texas Tech University System | Galectin-3c combination therapy for human cancer |
| US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| SG10201913777XA (en) | 2013-03-13 | 2020-03-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
| MX373301B (es) | 2013-10-31 | 2020-04-24 | Sanofi Sa | Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos. |
| SG10201913447SA (en) | 2013-10-31 | 2020-02-27 | Sanofi Sa | Specific anti-cd38 antibodies for treating human cancers |
| IL285110B2 (en) | 2019-01-28 | 2025-11-01 | Sanofi Sa | Methods of treating multiple myeloma |
| IL302640A (en) | 2020-11-03 | 2023-07-01 | Sanofi Aventis Us Llc | Use of isatuximab for the treatment of multiple myeloma |
| KR20250029015A (ko) | 2022-03-07 | 2025-03-04 | 사노피-아벤티스 유.에스. 엘엘씨 | 다발성 골수종의 치료를 위한, 다른 제제와 조합된 이사툭시맙의 용도 |
-
2014
- 2014-03-13 SG SG10201913777XA patent/SG10201913777XA/en unknown
- 2014-03-13 EP EP20180210.5A patent/EP3769783A1/en not_active Withdrawn
- 2014-03-13 SG SG11201506956TA patent/SG11201506956TA/en unknown
- 2014-03-13 MY MYPI2015702949A patent/MY175418A/en unknown
- 2014-03-13 CN CN202010773679.3A patent/CN112043826A/zh active Pending
- 2014-03-13 PT PT147732705T patent/PT2968555T/pt unknown
- 2014-03-13 KR KR1020157027249A patent/KR102241868B1/ko active Active
- 2014-03-13 RU RU2015143462A patent/RU2670127C2/ru active
- 2014-03-13 IL IL241407A patent/IL241407B/en unknown
- 2014-03-13 EP EP14773270.5A patent/EP2968555B1/en active Active
- 2014-03-13 RU RU2018134595A patent/RU2723937C2/ru active
- 2014-03-13 IL IL292978A patent/IL292978A/en unknown
- 2014-03-13 AU AU2014244333A patent/AU2014244333B2/en active Active
- 2014-03-13 JP JP2016501850A patent/JP6279065B2/ja active Active
- 2014-03-13 ES ES14773270T patent/ES2808565T3/es active Active
- 2014-03-13 CA CA2904630A patent/CA2904630A1/en not_active Abandoned
- 2014-03-13 CN CN201480024843.3A patent/CN105407921A/zh active Pending
- 2014-03-13 PL PL14773270T patent/PL2968555T3/pl unknown
- 2014-03-13 CN CN202510798995.9A patent/CN120860201A/zh active Pending
- 2014-03-13 MX MX2015012297A patent/MX373308B/es active IP Right Grant
- 2014-03-13 WO PCT/US2014/025441 patent/WO2014159911A1/en not_active Ceased
- 2014-03-13 KR KR1020217010487A patent/KR20210043006A/ko not_active Ceased
- 2014-03-13 SG SG10201707464SA patent/SG10201707464SA/en unknown
- 2014-03-13 US US14/775,641 patent/US20160022813A1/en not_active Abandoned
-
2015
- 2015-10-01 ZA ZA2015/07310A patent/ZA201507310B/en unknown
-
2016
- 2016-12-22 US US15/389,279 patent/US20170106085A1/en not_active Abandoned
-
2019
- 2019-04-04 US US16/375,693 patent/US20190321471A1/en not_active Abandoned
-
2021
- 2021-05-19 US US17/324,478 patent/US12533411B2/en active Active
-
2025
- 2025-12-12 US US19/417,983 patent/US20260207738A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506388A5 (enExample) | ||
| RU2018134595A (ru) | Композиции, включающие антитела к cd38 и карфилзомиб | |
| JP2017048208A5 (enExample) | ||
| RU2015127089A (ru) | Композиции, содержащие антитела к cd38 и леналидомид | |
| JP2021526136A5 (enExample) | ||
| CL2019002056A1 (es) | Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650) | |
| EA201891489A1 (ru) | Фармацевтическая композиция, содержащая аморфный леналидомид и антиоксидант | |
| RU2015110981A (ru) | Комбинации и их применение | |
| JP2016536314A5 (enExample) | ||
| HRP20200745T1 (hr) | Agensi koji vezuju cd123 i njihove upotrebe | |
| EA201691516A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
| NZ607473A (en) | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl | |
| EA201790597A1 (ru) | Способы лечения вирусных инфекций filoviridae | |
| JP2017528462A5 (enExample) | ||
| PE20141271A1 (es) | Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2 | |
| HRP20191115T1 (hr) | Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora | |
| JP2012136541A5 (enExample) | ||
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| HRP20210552T1 (hr) | Liječenje multiplog mijeloma (mm) | |
| WO2016022589A3 (en) | Methods for treating multiple myeloma | |
| JP2010500370A5 (enExample) | ||
| JP2020502198A5 (enExample) | ||
| JP2020533383A5 (enExample) | ||
| HRP20201632T4 (hr) | Režimi doziranja melflufena kod raka | |
| PE20231082A1 (es) | Muteinas de il-10 y proteinas de fusion de las mismas referencia cruzada a solicitudes relacionadas |